Vertex Pharmaceuticals Inc. says it is "not surprised" that NICE has issued draft guidance not recommending Orkambi (lumacaftor/ivacaftor) for use on the NHS in England.
"Since the beginning of our discussions with NICE, Vertex has made clear our belief that the single technology appraisal process...






![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
